

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6809934

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BIOPHARMA CREDIT PLC	06/30/2021
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BRAINTREE LABORATORIES, INC
<b>Street Address:</b>	60 COLUMBIAN STREET, WEST
<b>City:</b>	BRAINREE
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02185
<b>PROPERTY NUMBERS Total: 8</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	7291324
Patent Number:	6946149
Patent Number:	10143656
Patent Number:	11033498
Patent Number:	6930119
Patent Number:	6645481
Application Number:	16408014
Application Number:	14173144
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	17813348531
<b>Email:</b>	david.chavous@sebelapharma.com
<b>Correspondent Name:</b>	DAVID A CHAVOUS
<b>Address Line 1:</b>	60 COLUMBIAN STREET, WEST
<b>Address Line 4:</b>	BRAINREE, MASSACHUSETTS 02185
<b>NAME OF SUBMITTER:</b>	DAVID A CHAVOUS
<b>SIGNATURE:</b>	/David A Chavous/
<b>DATE SIGNED:</b>	07/13/2021

**Total Attachments: 16**

source=BraintreePatentRelease#page1.tif  
source=BraintreePatentRelease#page2.tif  
source=BraintreePatentRelease#page3.tif  
source=BraintreePatentRelease#page4.tif  
source=BraintreePatentRelease#page5.tif  
source=BraintreePatentRelease#page6.tif  
source=BraintreePatentRelease#page7.tif  
source=BraintreePatentRelease#page8.tif  
source=BraintreePatentRelease#page9.tif  
source=BraintreePatentRelease#page10.tif  
source=BraintreePatentRelease#page11.tif  
source=BraintreePatentRelease#page12.tif  
source=BraintreePatentRelease#page13.tif  
source=BraintreePatentRelease#page14.tif  
source=BraintreePatentRelease#page15.tif  
source=BraintreePatentRelease#page16.tif

## TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS

This TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS (this “Termination and Release”) dated as of June 30, 2021, is made by BIOPHARMA CREDIT PLC, as collateral agent for the Secured Parties (in such capacity, the “Collateral Agent”), in favor of BRAINTREE LABORATORIES, INC. (the “Grantor”).

### RECITALS:

WHEREAS, the Grantor is a party to that certain Guarantee and Security Agreement, dated as of May 1, 2018 (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Guarantee and Security Agreement”; terms used in this Termination and Release and not otherwise defined herein have the meanings set forth in the Guarantee and Security Agreement), by and among the Grantor, the other grantors party thereto, and the Collateral Agent pursuant to which each Grantor granted a security interest to the Collateral Agent in the Patent Collateral (as defined below), including, but not limited to, those Patents listed on Schedule A hereto;

WHEREAS, the Grantor entered into that certain Patent Security Agreement, dated as of May 1, 2018, as amended and restated on May 29, 2020 (the “Patent Security Agreement”), granting the Collateral Agent security interests in and liens on certain patents described therein (the “Patent Collateral”);

WHEREAS, the Patent Security Agreement was recorded with the United States Patent and Trademark Office (“USPTO”) on May 1, 2018 at Reel/Frame 046050/0242;

WHEREAS, the Grantor has requested that the Collateral Agent enter into this Termination and Release in order to effectuate, evidence and record the release and reassignment to the Grantor of any and all right, title and interest the Collateral Agent may have in the Patent Collateral pursuant to the Patent Security Agreement;

WHEREAS, the Collateral Agent desires to terminate and release its security interest in the Patent Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent hereby agrees:

SECTION 1. Release of Security Interest. The Collateral Agent hereby releases, terminates and discharges all liens and security interests the Collateral Agent has in, to and under the Patent Collateral under the Patent Security Agreement.

SECTION 2. Filing the Release. The Collateral Agent authorizes and requests that this Termination and Release be filed and recorded at the USPTO at the Grantor’s sole cost and expense.

SECTION 3. Counterparts; Electronic Transmission. This Termination and Release may be executed and delivered by facsimile or other means of electronic transmission and such transmission shall constitute an original for all purposes.

SECTION 4. Governing Law. THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.


[Signature page follows this page.]

IN WITNESS WHEREOF, the undersigned has executed this Termination and Release by its duly authorized officer as of the date first above written.

BIOPHARMA CREDIT PLC,  
as Collateral Agent

By: Pharmakon Advisors, LP,  
its Investment Manager

By: Pharmakon Management I, LLC,  
its General Partner

By:   
Name: Pedro Gonzalez de Cosio  
Title: Managing Member

[Signature Page to Termination and Release of Security Agreement in Patents]

742181994

**PATENT**  
**REEL: 056838 FRAME: 0252**

Schedule A  
Patent Collateral

Patent Registrations

<b>Present Owner</b>	<b>Country</b>	<b>Title</b>	<b>Filing Date</b>	<b>Status</b>	<b>Patent/Application Number</b>
Braintree Laboratories, Inc.	Austria	KIT COMPRISING AN OSMOTIC LAXATIVE AND A STIMULANT LAXATIVE FOR PREPARING THE COLON FOR VIRTUAL COLONOSCOPY	12/22/2006	Granted	1976520
Braintree Laboratories, Inc.	European Patent Convention	KIT COMPRISING AN OSMOTIC LAXATIVE AND A STIMULANT LAXATIVE FOR PREPARING THE COLON FOR VIRTUAL COLONOSCOPY	12/22/2006	Granted	1976520
Braintree Laboratories, Inc.	Turkey	KIT COMPRISING AN OSMOTIC LAXATIVE AND A STIMULANT LAXATIVE FOR PREPARING THE COLON FOR VIRTUAL COLONOSCOPY	12/22/2006	Granted	1976520
Braintree Laboratories, Inc.	Denmark	KIT COMPRISING AN OSMOTIC LAXATIVE AND A STIMULANT LAXATIVE FOR PREPARING THE COLON FOR VIRTUAL COLONOSCOPY	12/22/2006	Granted	1976520

<b>Present Owner</b>	<b>Country</b>	<b>Title</b>	<b>Filing Date</b>	<b>Status</b>	<b>Patent/Application Number</b>
Braintree Laboratories, Inc.	France	KIT COMPRISING AN OSMOTIC LAXATIVE AND A STIMULANT LAXATIVE FOR PREPARING THE COLON FOR VIRTUAL COLONOSCOPY	12/22/2006	Granted	1976520
Braintree Laboratories, Inc.	United Kingdom	KIT COMPRISING AN OSMOTIC LAXATIVE AND A STIMULANT LAXATIVE FOR PREPARING THE COLON FOR VIRTUAL COLONOSCOPY	12/22/2006	Granted	1976520
Braintree Laboratories, Inc.	Germany	KIT COMPRISING AN OSMOTIC LAXATIVE AND A STIMULANT LAXATIVE FOR PREPARING THE COLON FOR VIRTUAL COLONOSCOPY	12/22/2006	Granted	1976520
Braintree Laboratories, Inc.	Finland	KIT COMPRISING AN OSMOTIC LAXATIVE AND A STIMULANT LAXATIVE FOR PREPARING THE COLON FOR VIRTUAL COLONOSCOPY	12/22/2006	Granted	1976520
Braintree Laboratories, Inc.	Belgium	KIT COMPRISING AN OSMOTIC LAXATIVE AND A STIMULANT LAXATIVE FOR PREPARING THE COLON FOR	12/22/2006	Granted	1976520

<b>Present Owner</b>	<b>Country</b>	<b>Title</b>	<b>Filing Date</b>	<b>Status</b>	<b>Patent/Application Number</b>
		VIRTUAL COLONOSCOPY			
Braintree Laboratories, Inc.	Sweden	KIT COMPRISING AN OSMOTIC LAXATIVE AND A STIMULANT LAXATIVE FOR PREPARING THE COLON FOR VIRTUAL COLONOSCOPY	12/22/2006	Granted	1976520
Braintree Laboratories, Inc.	United States of America	METHOD OF BOWEL CLEANSING	10/22/2002	Granted	7291324
Braintree Laboratories, Inc.	Austria	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690
Braintree Laboratories, Inc.	Turkey	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	TR201719996T4
Braintree Laboratories, Inc.	Croatia	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690
Braintree Laboratories, Inc.	Czech Republic	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690
Braintree Laboratories, Inc.	Denmark	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690
Braintree Laboratories, Inc.	Spain	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	300257920
Braintree Laboratories, Inc.	Portugal	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	20171000083051
Braintree Laboratories, Inc.	France	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690
Braintree Laboratories, Inc.	United Kingdom	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690



<b>Present Owner</b>	<b>Country</b>	<b>Title</b>	<b>Filing Date</b>	<b>Status</b>	<b>Patent/Application Number</b>
Braintree Laboratories, Inc.	Switzerland	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690
Braintree Laboratories, Inc.	Liechtenstein	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690
Braintree Laboratories, Inc.	Ireland	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690
Braintree Laboratories, Inc.	Italy	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690
Braintree Laboratories, Inc.	Luxembourg	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690
Braintree Laboratories, Inc.	Greece	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690
Braintree Laboratories, Inc.	Netherlands	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690
Braintree Laboratories, Inc.	Germany	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	602012038156.6
Braintree Laboratories, Inc.	Belgium	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690
Braintree Laboratories, Inc.	Sweden	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690
Braintree Laboratories, Inc.	European Patent Convention	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Granted	2696690
Braintree Laboratories, Inc.	European Patent Convention	SULFATE SALTS AS TRANSIT TIME ENHANCER	4/16/2012	Published	3292763 A1
Braintree Laboratories, Inc.	Japan	SULFATE SALTS AS TRANSIT TIME ENHANCER	3/14/2016	Granted	6189463
Braintree Laboratories, Inc.	Hong Kong	SULFATE SALTS AS TRANSIT TIME ENHANCER	9/13/2018	Pending	18111776.7

<b>Present Owner</b>	<b>Country</b>	<b>Title</b>	<b>Filing Date</b>	<b>Status</b>	<b>Patent/Application Number</b>
Braintree Laboratories, Inc.	Japan	SULFATE SALTS AS TRANSIT TIME ENHANCER	8/2/2017	Granted	6356324
Braintree Laboratories, Inc.	Japan	SULFATE SALTS AS TRANSIT TIME ENHANCER	6/13/2018	Published	2018-112399
Braintree Laboratories, Inc.	Russian Federation	SULFATE SALTS AS TRANSIT TIME ENHANCER	5/22/2018	Pending	2018118808
Braintree Laboratories, Inc.	Russian Federation	SULFATE SALTS AS TRANSIT TIME ENHANCER	1/30/2017	Granted	2655886
Braintree Laboratories, Inc.	United States of America	SALT SOLUTION FOR COLON CLEANSING	4/30/2002	Granted	6,946,149
Braintree Laboratories, Inc.	United States of America	SALT SOLUTION FOR COLON CLEANSING	10/15/2008	Granted	6,946,149
Braintree Laboratories, Inc.	Austria	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Monaco	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Hungary	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Cyprus, Republic of	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Australia	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	2003231160
Braintree Laboratories, Inc.	Canada	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	2484303
Braintree Laboratories, Inc.	European Patent Convention	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Estonia	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331

<b>Present Owner</b>	<b>Country</b>	<b>Title</b>	<b>Filing Date</b>	<b>Status</b>	<b>Patent/Application Number</b>
Braintree Laboratories, Inc.	Bulgaria	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Slovakia	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Slovenia	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Romania	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Czech Republic	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Turkey	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Denmark	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Spain	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Portugal	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	France	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	United Kingdom	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Switzerland	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Liechtenstein	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Ireland	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331

<b>Present Owner</b>	<b>Country</b>	<b>Title</b>	<b>Filing Date</b>	<b>Status</b>	<b>Patent/Application Number</b>
Braintree Laboratories, Inc.	Italy	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Luxembourg	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Greece	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Netherlands	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Germany	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Finland	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Belgium	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Sweden	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	1499331
Braintree Laboratories, Inc.	Hong Kong	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	HK1148935
Braintree Laboratories, Inc.	Hong Kong	SALT SOLUTION FOR COLON CLEANSING	4/28/2003	Granted	11154492
Braintree Laboratories, Inc.	European Patent Convention	SALT SOLUTION FOR COLON CLEANSING	9/29/2010	Granted	2,292,244
Braintree Laboratories, Inc.	Hong Kong	SALT SOLUTION FOR COLON CLEANSING	16-Aug-11	Granted	HK1148935
Braintree Laboratories, Inc.	Hong Kong	SALT SOLUTION FOR COLON CLEANSING	8/16/2011	Granted	HK1154492
Braintree Laboratories, Inc.	Canada	METHOD FOR TREATING IRRITABLE BOWEL SYNDROME	7/9/2004	Granted	2,531,445

<b>Present Owner</b>	<b>Country</b>	<b>Title</b>	<b>Filing Date</b>	<b>Status</b>	<b>Patent/Application Number</b>
Braintree Laboratories, Inc.	European Patent Convention	METHOD FOR TREATING IRRITABLE BOWEL SYNDROME	7/9/2004	Granted (all validations lapsed/to be allowed to lapse)	1,663,257
Braintree Laboratories, Inc.	United States of America	METHOD OF ACHIEVING OVERNIGHT LAXATION AND CONTROL OF BOWEL FUNCTION	28-Sep-00	Granted	6,645,481
Braintree Laboratories, Inc.	European Patent Convention	USE OF POLYETHYLENE GLYCOL FOR REDUCING OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION	30-Mar-00	Granted	1048297
Braintree Laboratories, Inc.	European Patent Convention	USE OF POLYETHYLENE GLYCOL FOR REDUCING OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION	27-Sep-01	Published	1326592
Braintree Laboratories, Inc.	Germany	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	9/27/2001	Granted	60135001.4
Braintree Laboratories, Inc.	Portugal	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE	9/27/2001	Granted	1326592

<b>Present Owner</b>	<b>Country</b>	<b>Title</b>	<b>Filing Date</b>	<b>Status</b>	<b>Patent/Application Number</b>
		TREATMENT OF CONSTIPATION			
Braintree Laboratories, Inc.	Slovenia	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	9/27/2001	Granted	P 200130868
Braintree Laboratories, Inc.	Spain	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	9/27/2001	Granted	2310190
Braintree Laboratories, Inc.	Denmark	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	9/27/2001	Granted	1326592
Braintree Laboratories, Inc.	Austria	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	4/2/2003	Granted	E-0 401 900
Braintree Laboratories, Inc.	Monaco	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING	4/2/2003	Granted	1326592

<b>Present Owner</b>	<b>Country</b>	<b>Title</b>	<b>Filing Date</b>	<b>Status</b>	<b>Patent/Application Number</b>
		OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION			
Braintree Laboratories, Inc.	Cyprus	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	4/2/2003	Granted	1326592
Braintree Laboratories, Inc.	Romania	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	4/2/2003	Granted	1032027
Braintree Laboratories, Inc.	Turkey	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	4/2/2003	Granted	2008/07669
Braintree Laboratories, Inc.	Lithuania	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	4/2/2003	Granted	1326592
Braintree Laboratories, Inc.	France	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE	4/2/2003	Granted	1326592

<b>Present Owner</b>	<b>Country</b>	<b>Title</b>	<b>Filing Date</b>	<b>Status</b>	<b>Patent/Application Number</b>
		MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION			
Braintree Laboratories, Inc.	United Kingdom	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	4/2/2003	Granted	1326592
Braintree Laboratories, Inc.	Switzerland	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	4/2/2003	Granted	1326592
Braintree Laboratories, Inc.	Ireland	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	4/2/2003	Granted	1326592
Braintree Laboratories, Inc.	Italy	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	4/2/2003	Granted	1326592
Braintree Laboratories, Inc.	Luxembourg	USE OF POLYETHYLENE GLYCOL (PEG) FOR	4/2/2003	Granted	1326592



<b>Present Owner</b>	<b>Country</b>	<b>Title</b>	<b>Filing Date</b>	<b>Status</b>	<b>Patent/Application Number</b>
		THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION			
Braintree Laboratories, Inc.	Greece	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	4/2/2003	Granted	3066963
Braintree Laboratories, Inc.	Netherlands	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	4/2/2003	Granted	1326592
Braintree Laboratories, Inc.	Finland	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	4/2/2003	Granted	1326592
Braintree Laboratories, Inc.	Belgium	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	4/2/2003	Granted	1326592

<b>Present Owner</b>	<b>Country</b>	<b>Title</b>	<b>Filing Date</b>	<b>Status</b>	<b>Patent/Application Number</b>
Braintree Laboratories, Inc.	Sweden	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	4/2/2003	Granted	1326592
Braintree Laboratories, Inc.	Latvia	USE OF POLYETHYLENE GLYCOL (PEG) FOR THE MANUFACTURING OF MEDICAMENT FOR THE TREATMENT OF CONSTIPATION	4/2/2003	Granted	1326592
Braintree Laboratories Inc.	United States of America	SOLID ORAL FORMULATIONS FOR CLEANSING A COLON AND METHODS OF USING THE SAME	8/4/2017	Granted	10,143,656
Braintree Laboratories Inc.	United States of America	SOLID ORAL FORMULATIONS FOR CLEANSING A COLON AND METHODS OF USING THE SAME	12/3/2018	Pending	16/207,800
Braintree Laboratories Inc.	United States of America	SULFATE TABLET COMPOSITIONS AND METHODS OF USING THE SAME	2/5/2014	Pending	14/173,144
Braintree Laboratories, Inc.	United States of America	COLON CLEANSING COMPOSITION AND METHODS OF USING SAME	5/9/2019	Pending	16/408,014
Braintree Laboratories, Inc.	United States of America	LIQUID PHARMACEUTICAL COMPOSITION	7/17/2002	Granted	6930119